2025 Annual Meeting | Industry Therapeutic Update from Eisai Inc.: Talking with Patients and Care Partners About Early AD Treatment: Communicating the Rationale for Early, Ongoing Therapy

Date Sunday 04/06/25

Time 11:45 AM - 12:45 PM PDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology, Aging, Dementia, and Behavioral Neurology

Learning Objectives The earlier that mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia are identified and treated, the greater the opportunity for patient benefit. Further, because AD is a progressive neurodegenerative disease and toxic proteins continue to accumulate over time, ongoing treatment is critical. This program takes a case-based approach to exploring the benefits of a treatment option for early AD and discussing the rationale for early and ongoing therapy with patients and care partners.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Event Timeline
11:45 AM - 12:45 PM PDT	Speaker	Industry Therapeutic Update from Eisai Inc.: Talking with Patients and Care Partners

��ɫ��

��ɫ��